CELYAD SA/ADR (NASDAQ:CYAD) – Equities research analysts at SunTrust Banks issued their FY2023 EPS estimates for shares of CELYAD SA/ADR in a note issued to investors on Monday, March 18th. SunTrust Banks analyst P. Lawson forecasts that the company will post earnings of ($0.91) per share for the year.
Several other research firms also recently commented on CYAD. William Blair reissued a “buy” rating on shares of CELYAD SA/ADR in a research note on Tuesday, December 4th. Zacks Investment Research downgraded shares of CELYAD SA/ADR from a “buy” rating to a “hold” rating in a research note on Tuesday, January 29th. Finally, HC Wainwright lifted their price target on shares of CELYAD SA/ADR from $46.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. CELYAD SA/ADR presently has an average rating of “Buy” and an average target price of $45.40.
CYAD stock opened at $21.87 on Wednesday. The company has a market cap of $222.52 million, a price-to-earnings ratio of -6.18 and a beta of 1.83. CELYAD SA/ADR has a one year low of $15.36 and a one year high of $37.20.
Several hedge funds have recently bought and sold shares of the business. Millennium Management LLC raised its stake in shares of CELYAD SA/ADR by 69.6% during the fourth quarter. Millennium Management LLC now owns 90,597 shares of the company’s stock worth $1,645,000 after acquiring an additional 37,171 shares in the last quarter. Victory Capital Management Inc. raised its stake in shares of CELYAD SA/ADR by 4.1% during the fourth quarter. Victory Capital Management Inc. now owns 646,351 shares of the company’s stock worth $11,738,000 after acquiring an additional 25,189 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of CELYAD SA/ADR by 1,109.0% during the third quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock worth $160,000 after acquiring an additional 5,545 shares in the last quarter. 7.62% of the stock is currently owned by hedge funds and other institutional investors.
About CELYAD SA/ADR
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Featured Article: Bull Market
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.